entertainment -WSS

entertainment

author：knowledge 2025-10-01 13:58:25 - browse：89

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Study identifies new proteins linked to dementia risk 25 years later

focus

knowledge

WSS

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Physician executives need more than on

When women are denied an abortion, their children fare worse than peers

VC firm General Catalyst wants to buy a health system

Sana to lay off nearly a third of staff, de

FDA rejects Alnylam's heart disease treatment over insufficient data

explore

entertainment

leisure time

What does generative AI mean for health care? We asked experts

VC firm General Catalyst wants to buy a health system

Medicare proposal to cover medical devices draws a mixed reaction

Liquid biopsy for lung cancer is launched by Delfi

Medicare details structure of new drug price negotiation program

What to expect at HLTH 2023, the health care industry conference

The cancer drug shortage isn’t new — and neither are the solutions

Why Charlie Gard's case is so disturbing to Americans

How one medical school became remarkably diverse

Affordable Connectivity Program vital to health care, experts say

leisure time

FDA panel signals lack of confidence in Amgen cancer drug data

Senate panel eyes new effort on drug shortages

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Chemotherapy drug shortage eases slightly but still widespread

Study identifies new proteins linked to dementia risk 25 years later

focus

knowledge

knowledge

hotspot